In two phase III trials, the mTOR inhibitor temsirolimus failed to improved progression-free survival outcomes for patients with metastatic renal cell carcinoma compared with other therapeutic options.
Women who developed a rash early in their treatment for HER2-positive breast cancer with lapatinib were more likely to go on to have pathologic complete response compared to those who did not get a rash, according to the results of an unplanned analysis of data from the NeoALTTO trial.
A new study shows that men who have a specific protein marker present in their prostate biopsy may benefit from close follow-up and additional biopsies as they may be at increased risk of developing cancer.
Concurrent administration of trastuzumab and anthracyclines resulted in a similar rate of pathologic complete response when compared to sequential administration in women with HER2-positive breast cancer, according to the results of a new study.
Following recent trial data showing an increased risk of dangerous blood clots with ponatinib, which led the FDA to request that the manufacturer stop marketing the drug, the FDA’s European counterpart has adjusted its recommendations for ponatinib but has not changed its “positive opinion” that led to the approval.